# Insilico Medicine

> Insilico Medicine is a clinical-stage biotechnology company using generative AI and laboratory experimentation to discover targets and design drug candidates. It licenses its Pharma.AI software, collaborates with pharmaceutical companies and develops an internal pipeline; its fibrosis candidate rentosertib entered Phase III in September 2026.

- **Founded:** 2014
- **Headquarters:** Cambridge, United States; Hong Kong, China
- **Founders:** Alex Zhavoronkov (Founder, Chairman, Co-CEO and Chief Business Officer), Alex Aliper (Scientific co-founder and President)
- **Products:** PandaOmics, Chemistry42, inClinico, Drug discovery collaborations and pipeline licensing, Rentosertib
- **Notable:** Published experimental DDR1 inhibitor design and validation work in Nature Biotechnology in 2019., Published the TNIK discovery and preclinical/Phase I program in Nature Biotechnology in 2024., Published a randomized 71-patient rentosertib Phase IIa trial in Nature Medicine in 2025.

## Products & services

- **PandaOmics** — Target and biomarker discovery using multi-omics, biological networks and biomedical literature.
- **Chemistry42** — Generative molecular design and optimization combined with computational and medicinal chemistry.
- **inClinico** — Multimodal forecasting of clinical trial outcomes, including Phase II to Phase III transition.
- **Drug discovery collaborations and pipeline licensing** — Partner-funded discovery, co-development and licensing of internally developed therapeutic candidates.
- **Rentosertib** — Investigational TNIK inhibitor for idiopathic pulmonary fibrosis; Phase III first patient dosed in September 2026. Not an approved medicine.
- **LongevityBench, Longevity LLM and Longevity Claw** — Research resources introduced with a September 2026 Cell publication to support longevity discovery.

## Achievements

- Published experimental DDR1 inhibitor design and validation work in Nature Biotechnology in 2019.
- Published the TNIK discovery and preclinical/Phase I program in Nature Biotechnology in 2024.
- Published a randomized 71-patient rentosertib Phase IIa trial in Nature Medicine in 2025.
- Listed on HKEX on December 30, 2025, stock code 3696.
- Announced first patient dosed in rentosertib Phase III on September 10, 2026.

## Latest updates

- **2026-09** — First patient dosed in GENESIS-IPF-3; planned 320 participants across 47 Chinese centers, with 52-week treatment and annual FVC decline as primary endpoint.
- **2026-09** — Aging-clock analysis of Phase IIa proteomic data reported changes in predicted biological age; this does not establish longer lifespan or benefit in healthy people.
- **2026-09** — Introduced LongevityBench, Longevity LLM and Longevity Claw with a Cell publication.
- **2026-08** — Reported first-half 2026 revenue of US$106.3 million and net profit of US$35.54 million.
- **2026-06** — Announced a neuroimmune discovery collaboration with SK Biopharmaceuticals.
- **2026-03** — Announced a worldwide portfolio license and discovery collaboration with Lilly.

## Links

- Website: https://insilico.com/
- LinkedIn: https://www.linkedin.com/company/in-silico-medicine/
- Twitter/X: https://x.com/InSilicoMeds
- GitHub: https://github.com/insilicomedicine
- YouTube: https://www.youtube.com/c/InsilicoMedicine
- Instagram: https://www.instagram.com/insilicomedicine/
- Facebook: https://www.facebook.com/insilicomedicine

---

Profile page: https://yespress.io/insilico-medicine
Published by YesPress — https://yespress.io
Last updated: 2026-10-02